Change search
ReferencesLink to record
Permanent link

Direct link
Pre-clinical evaluation of -benzyl-DOTA-ZHER2: 3429 a potential agent for imaging of HER2 expression in malignant tumors
Show others and affiliations
2007 (English)In: International Journal of Molecular Medicine, ISSN 1107-3756, E-ISSN 1791-244X, Vol. 20, no 3, 397-404 p.Article in journal (Refereed) Published
Abstract [en]

Imaging of expression of human epidermal growth factor receptor type 2 (HER2) in breast carcinomas may help to select patients eligible for trastuzumab therapy. The Affibody molecule Z(HER2:342) is a small (7-kDa) non-immunoglobulin affinity protein, which binds to HER2 with a picomolar affinity. Previously, a benzyl-DTPA conjugate of Z(HER2:342) was labeled with In-111 and demonstrated good targeting in murine xenografts. We considered that the use of the macrocyclic chelator DOTA could increase the label stability and enhance a choice of nuclides, which could be used as a label for Z(HIR2:342). The goal of this study was the preparation and pre-clinical evaluation of the indium- 111 labeled DOTA-derivative of Z(HER2:342)- Isothiocyanate-benzyl-DOTA was coupled to recombinant Z(HER2:342), and the conjugate was efficiently labeled with In-111 at 60 degrees C. The specificity of In-111-benzyl-DOTA-Z(HER2:342) binding to HER2 was confirmed in vitro using HER2-expressing breast carcinoma BT474 and ovarian carcinoma SKOV-3 cell lines. Biodistribution of In-111-benzyl-DOTA-Z(HER2:342) was performed in nude mice bearinLy LS174T xenografts and compared directly with the biodistribution of In-111-benzyl-DTPA-Z(HR2:342). In vivo, In-111-benzyl-DOTA-Z(HER2:312) demonstrated quick clearance from blood and non-specific organs except the kidneys. Four hours post injection (pi), the tumor uptake of In-111-benzyl-DOTA-Z(HER2:342) (4.4 +/- 1.0% IA/g) was specific and the tumor-to-blood ratio was 23. The use of benzyl-DTPA provided higher tumor-to-blood and tumor-to-liver ratios. gamma-camera imaging showed clear visualization of HER2-expressing xenografts using In-111-benzyl-DOTA-Z(HER2:342). In-111-benzyl-DOTA-Z(HER2:342) has a potential for imaging of HER2 expression in malignant tumors.

Place, publisher, year, edition, pages
2007. Vol. 20, no 3, 397-404 p.
Keyword [en]
affibody, human epidermal growth factor receptor type 2, tumor targeting, indium-111, benzyl-DOTA, disseminated peritoneal disease, breast-cancer xenografts, binding-proteins, in-vitro, affibody, antibody, trastuzumab, therapy, in-111, mice
National Category
Medical Biotechnology
URN: urn:nbn:se:kth:diva-16865ISI: 000248699900018PubMedID: 17671747ScopusID: 2-s2.0-35148899326OAI: diva2:334908

QC 20100525

Available from: 2010-08-05 Created: 2010-08-05 Last updated: 2014-11-11Bibliographically approved

Open Access in DiVA

No full text


Search in DiVA

By author/editor
Eriksson Karlström, Amelie
By organisation
Molecular Biotechnology (closed 20130101)
In the same journal
International Journal of Molecular Medicine
Medical Biotechnology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 29 hits
ReferencesLink to record
Permanent link

Direct link